Chronic Lymphocytic LeukemiaNCT04370457
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
A study testing Administration of the MyPal ePRO system in people with Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes, run by Centre for Research and Technology Hellas at 1 site in Italy.
Trial summary
Randomized unblinded interventional clinical trial: Arm Intervention Experimental arm (n=150): Intervention group Administration of the MyPal ePRO system the intervention group will use the ePRO tools provided in the project. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- What is being tested?
- Administration of the MyPal ePRO system
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jan 2021to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Adults (≥18 years)
- Diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or myelodysplastic syndrome (MDS)
- Scheduled to receive any line of treatment for CLL/SLL or MDS or who have been previously exposed to any treatment for CLL or MDS
- Able to understand and communicate in the respective language
- Users of an Internet connected device (smart phone/tablet)
Who cannot join
- Patients who are already participating in another experimental study
- Patients needing immediate referral for specialized palliative care
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
- Patients unable to provide written informed consent
- Life expectancy <3 months
- For CLL cohort: patients who have experienced Richter transformation
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
IRCCS Ospedale San Raffaele
Milan, 20132
Eloise Scarano, PhD, +39022643 ext. 3919, scarano.eloise@hsr.it
Lydia Scarfò, MD, +39022643 ext. 6119, scarfo.lydia@hsr.it
About this study
Official title: Randomized Clinical Trial of the MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Randomized unblinded interventional clinical trial:
Arm Intervention Experimental arm (n=150): Intervention group Administration of the MyPal ePRO system the intervention group will use the ePRO tools provided in the project.
Standard care arm (n=150): no intervention besides general palliative care if required general palliative care if required.
Patients will be randomly assigned in a 1:1 fashion to use the MyPal system and receive related-intervention versus general palliative care, stratified by cancer type (i.e. CLL vs MDS), using a computer-generated number sequence, which will be concealed until after group assignment.
Read the detailed description
The MyPal eHealth system coincides with the MyPal intervention. The system will be used primarily by the patients that participate in the intervention arm of the trial and secondarily by the participating healthcare professionals (HCP). Patients participating in the standard arm of the trial won't use the system. Access to the MyPal eHealth system will be granted to the patients and HCP right after their enrollment in the trial. Patients will have access to the system continuously for 12 months; HCP will have access to the system until the end of the trial.
The main modules (software and hardware) of the system are outlined below:
- MyPal smartphone application (app). This is the interface of the patient to the system. The MyPal smartphone app is available for smartphones running on the Android and iOS operating systems and it is installed on the personal smartphone of the patient.
- Commercial smart wristband. This is a commercial activity tracking device that will be employed for monitoring the physical activity and the sleep quality of the patient, provided by the site personnel. Wearable to be worn. Ionic™ (Fitbit) will be employed by the trial as the smart wristband.
- MyPal web application (app). This is the main interface of the HCP to the system. It is accessible as a web portal through any modern web browser.
- System backend. This module resides at the backend of the system and it is not directly accessible by the aforementioned types of users. The system backend interfaces the MyPal smartphone app and the MyPal web app.
In brief, the intervention revolves around the reporting by the patient of physical and psycho-emotional symptoms (via the MyPal smartphone app) and the immediate delivery of the reported symptom-related information to the HCP (via the MyPal web app). Of note, the reported symptom-related information becomes instantly available to the HCP in the MyPal web app; however, this does not imply that the HCP is guaranteed to review it at the same time. The intervention is described in more detailed below, first from the standpoint of the patient and then from that of the HCP.
The patients interact with the MyPal smartphone app in 3 sequential phases. Additionally, during the enrollment in the study, the patients are handed the commercial smart wristband and they are instructed to wear it as much as possible (also while sleeping) throughout their participation in the study.
Registration Phase. This phase is completed the first time the patient uses the MyPal smartphone app, which take place right after the patient is enrolled in the study. The mission of this phase is (1) to register the patient into the MyPal system, (2) to initially set a number of preferences, (3) to collect via self-reporting the baseline assessment of the patient's physical and psycho-emotional symptom, and (4) to screen for motivational targets and non-adherence risk. The smartphone app guides the patient throughout the entire registration process in a wizard-like fashion, where the user has to provide some information (1)-(2) and complete certain questionnaires (3)-(4). The latter is elaborated in the next phase.
Main usage phase. As soon as the registration phase is completed, the MyPal smartphone app enters into its main usage phase. This lasts 6 months (Month 0 to Month 6 of the patient's participation in the study) and, during this time, the patient is given access to a number of user-initiated functionalities (i.e., functionalities that the user has access to at all times) and system-initiated ones (i.e., functionalities for which the system decides when they become available to the user). More specifically, the functionalities of the second category are initiated via notifications that are presented by the smartphone app to the user. We can distinguish two main types of notifications, namely the intervention notifications (i.e., notifications associated with functionalities that are part of the interventions) and the assessment notifications (i.e., notifications informing the patient it's time to complete the assessment questionnaires that have been foreseen by the study protocol). The intervention notification frequency is once every a multiple of 1 week (e.g., 1 week, 2 weeks, 6 weeks), depending on the specific system-initiated functionality, while the intervention notifications are issued once per month. Whenever possible, messages concerning multiple functionalities are grouped in a single notification, either intervention notification or mixed one.
Follow-up usage phase. The follow-up usage phase starts immediately after the completion of the main usage phase and it also last 6 months (Month 7 to Month 12 of the patient's participation). This phase is identical to the previous phase (all the previously described functionalities are available) with a single exception. This is that the smartphone app does not issue assessment notification monthly; instead it issues only one such notification at the end of Month 12.
In contrast to the case of the patients, the HCP interact with the MyPal web app (i.e., their interface to the MyPal system) in the same manner throughout their participation in the study (this is considered to be from the first to the last month of the study). The only exception to this (main usage) is a short procedure that registers them into the MyPal system; the registration takes place the first time the HCP accesses the MyPal web app.
In brief, during the main usage of the MyPal web app, the HCP get access to the data that are collected by (1) the MyPal smartphone app and (2) the commercial smart wristband and stored in the system backend. The collected data become available to the MyPal web app as soon as they are stored. At individual level, the HCP is authorized to access only the data of the patients of the associated clinical center; however, access to aggregated and summarized data coming from all the patients (descriptive statistics such as min, max, average and percentiles) will also be provided to all the HCP. In contrast to the notification-heavy approach that was adopted for the patients, the HCP are not actively notified by the MyPal system at any point. To compensate for this, the study protocol mandates that the individual data of the participating patients of a given clinical center are reviewed by the associated HCP at least once every 72 hours. The data review and any action related to this will be recorded through the web interface. The absence of notifications means that all functionalities offered to the HCP are user-initiated.
- Being tested
- Administration of the MyPal ePRO system
- Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell, Myelodysplastic Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Administration of the MyPal ePRO systemOther
Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
| Study group | Role | What they receive |
|---|---|---|
| Experimental arm | Experimental | Administration of the MyPal ePRO system Receives: Other: Administration of the MyPal ePRO system |
| Standard care arm | No intervention | No further intervention besides standard palliative care approach if needed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire
The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire
Measured: through study completion, an average of 1 year
Improvement in EuroQol (EQ)-five dimensions (5D)
The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EuroQol (EQ)-five dimensions (5D).
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2020
- Study start1 Jan 2021
- Primary completion30 Jun 2022 (estimated)
- Study completion30 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Chronic Lymphocytic LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre for Research and Technology Hellas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paolo Ghia, MD,PhD, Principal investigator, IRCCS San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04370457
- Sponsor's protocol ID
- MyPAL4Adults
- Status last verified
- Jul 2021
- First submitted
- 25 Apr 2020
- Last updated
- 4 Aug 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chatzikonstantinou T, Vasilopoulou M, Kyrou D, Karakatsoulis G, Argyropaidas P, Besikli-Dimou S, Bonotis P, Chatzimina M, Didi J, Dimosthenous C, Garani-Papadatos T, Hoffman S, Kakalou C, Kazantzaki E, Kiefer S, Koumakis L, Ling J, Maramis C, Meyerheim M, Payne C, Papangelou C, Payne S, Pontikoglou C, Reston R, Ryblom H, Sander A, Schera F, Smedby KE, Zacharioudakis G, Chatzidimitriou A, Doubek M, Stavroyianni N, Ghia P, Papadaki HA, Rosenquist R, Graf N, Natsiavas P, Stamatopoulos K, Karamanidou C, Scarfo L. Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. JCO Oncol Pract. 2026 Jul;22(7):1227-1237. doi: 10.1200/OP-25-00087. Epub 2025 Aug 25.
PubMed 40854168Bonotis P, Angelidis P, Natsiavas P. Usability and User Experience Testing of a Co-Designed Electronic Patient-Reported Outcomes App ("MyPal for Adults") for Palliative Cancer Care: Mixed Methods Study. JMIR Hum Factors. 2025 Apr 24;12:e57342. doi: 10.2196/57342.
PubMed 40278640Payne S, Begovic D, Salifu Y, Nelson A, Payne C, Downing J, Natsiavas P, Ling J. Applying Digital Health in Cancer and Palliative Care in Europe: Policy Recommendations from an International Expert Workshop (MyPal Project). J Palliat Med. 2024 Feb;27(2):216-223. doi: 10.1089/jpm.2023.0309. Epub 2023 Sep 22.
PubMed 37738323Scarfo L, Karamanidou C, Doubek M, Garani-Papadatos T, Didi J, Pontikoglou C, Ling J, Payne C, Papadaki HAlpha, Rosenquist R, Stavroyianni N, Payne S, Ghia P, Natsiavas P, Maramis C, Stamatopoulos K. MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. BMJ Open. 2021 Nov 2;11(11):e050256. doi: 10.1136/bmjopen-2021-050256.
PubMed 34728446
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Clinical Trial of the MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
- ClinicalTrials.gov ID
- NCT04370457
- Acronym / sponsor ID
- MyPAL4Adults
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Centre for Research and Technology HellasUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 30 Jun 2022 (estimated)
- Study completion
- 30 Sep 2022 (estimated)
- First posted
- 1 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Randomized unblinded interventional clinical trial:
Arm Intervention Experimental arm (n=150): Intervention group Administration of the MyPal ePRO system the intervention group will use the ePRO tools provided in the project.
Standard care arm (n=150): no intervention besides general palliative care if required general palliative care if required.
Patients will be randomly assigned in a 1:1 fashion to use the MyPal system and receive related-intervention versus general palliative care, stratified by cancer type (i.e. CLL vs MDS), using a computer-generated number sequence, which will be concealed until after group assignment.
Detailed description
The MyPal eHealth system coincides with the MyPal intervention. The system will be used primarily by the patients that participate in the intervention arm of the trial and secondarily by the participating healthcare professionals (HCP). Patients participating in the standard arm of the trial won't use the system. Access to the MyPal eHealth system will be granted to the patients and HCP right after their enrollment in the trial. Patients will have access to the system continuously for 12 months; HCP will have access to the system until the end of the trial.
The main modules (software and hardware) of the system are outlined below:
- MyPal smartphone application (app). This is the interface of the patient to the system. The MyPal smartphone app is available for smartphones running on the Android and iOS operating systems and it is installed on the personal smartphone of the patient.
- Commercial smart wristband. This is a commercial activity tracking device that will be employed for monitoring the physical activity and the sleep quality of the patient, provided by the site personnel. Wearable to be worn. Ionic™ (Fitbit) will be employed by the trial as the smart wristband.
- MyPal web application (app). This is the main interface of the HCP to the system. It is accessible as a web portal through any modern web browser.
- System backend. This module resides at the backend of the system and it is not directly accessible by the aforementioned types of users. The system backend interfaces the MyPal smartphone app and the MyPal web app.
In brief, the intervention revolves around the reporting by the patient of physical and psycho-emotional symptoms (via the MyPal smartphone app) and the immediate delivery of the reported symptom-related information to the HCP (via the MyPal web app). Of note, the reported symptom-related information becomes instantly available to the HCP in the MyPal web app; however, this does not imply that the HCP is guaranteed to review it at the same time. The intervention is described in more detailed below, first from the standpoint of the patient and then from that of the HCP.
The patients interact with the MyPal smartphone app in 3 sequential phases. Additionally, during the enrollment in the study, the patients are handed the commercial smart wristband and they are instructed to wear it as much as possible (also while sleeping) throughout their participation in the study.
Registration Phase. This phase is completed the first time the patient uses the MyPal smartphone app, which take place right after the patient is enrolled in the study. The mission of this phase is (1) to register the patient into the MyPal system, (2) to initially set a number of preferences, (3) to collect via self-reporting the baseline assessment of the patient's physical and psycho-emotional symptom, and (4) to screen for motivational targets and non-adherence risk. The smartphone app guides the patient throughout the entire registration process in a wizard-like fashion, where the user has to provide some information (1)-(2) and complete certain questionnaires (3)-(4). The latter is elaborated in the next phase.
Main usage phase. As soon as the registration phase is completed, the MyPal smartphone app enters into its main usage phase. This lasts 6 months (Month 0 to Month 6 of the patient's participation in the study) and, during this time, the patient is given access to a number of user-initiated functionalities (i.e., functionalities that the user has access to at all times) and system-initiated ones (i.e., functionalities for which the system decides when they become available to the user). More specifically, the functionalities of the second category are initiated via notifications that are presented by the smartphone app to the user. We can distinguish two main types of notifications, namely the intervention notifications (i.e., notifications associated with functionalities that are part of the interventions) and the assessment notifications (i.e., notifications informing the patient it's time to complete the assessment questionnaires that have been foreseen by the study protocol). The intervention notification frequency is once every a multiple of 1 week (e.g., 1 week, 2 weeks, 6 weeks), depending on the specific system-initiated functionality, while the intervention notifications are issued once per month. Whenever possible, messages concerning multiple functionalities are grouped in a single notification, either intervention notification or mixed one.
Follow-up usage phase. The follow-up usage phase starts immediately after the completion of the main usage phase and it also last 6 months (Month 7 to Month 12 of the patient's participation). This phase is identical to the previous phase (all the previously described functionalities are available) with a single exception. This is that the smartphone app does not issue assessment notification monthly; instead it issues only one such notification at the end of Month 12.
In contrast to the case of the patients, the HCP interact with the MyPal web app (i.e., their interface to the MyPal system) in the same manner throughout their participation in the study (this is considered to be from the first to the last month of the study). The only exception to this (main usage) is a short procedure that registers them into the MyPal system; the registration takes place the first time the HCP accesses the MyPal web app.
In brief, during the main usage of the MyPal web app, the HCP get access to the data that are collected by (1) the MyPal smartphone app and (2) the commercial smart wristband and stored in the system backend. The collected data become available to the MyPal web app as soon as they are stored. At individual level, the HCP is authorized to access only the data of the patients of the associated clinical center; however, access to aggregated and summarized data coming from all the patients (descriptive statistics such as min, max, average and percentiles) will also be provided to all the HCP. In contrast to the notification-heavy approach that was adopted for the patients, the HCP are not actively notified by the MyPal system at any point. To compensate for this, the study protocol mandates that the individual data of the participating patients of a given clinical center are reviewed by the associated HCP at least once every 72 hours. The data review and any action related to this will be recorded through the web interface. The absence of notifications means that all functionalities offered to the HCP are user-initiated.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental arm | Experimental | Other: Administration of the MyPal ePRO systemAdministration of the MyPal ePRO system |
| Standard care arm | No intervention | –No further intervention besides standard palliative care approach if needed |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Adults (≥18 years)
- Diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or myelodysplastic syndrome (MDS)
- Scheduled to receive any line of treatment for CLL/SLL or MDS or who have been previously exposed to any treatment for CLL or MDS
- Able to understand and communicate in the respective language
- Users of an Internet connected device (smart phone/tablet)
Key exclusion criteria (6 listed)
- Patients who are already participating in another experimental study
- Patients needing immediate referral for specialized palliative care
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
- Patients unable to provide written informed consent
- Life expectancy <3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Administration of the MyPal ePRO systemPatients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up | Other | Experimental arm |
Primary outcome
Improvement in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire
Time frame: through study completion, an average of 1 year
The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire
Improvement in EuroQol (EQ)-five dimensions (5D)
Time frame: through study completion, an average of 1 year
The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EuroQol (EQ)-five dimensions (5D).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2021.
- Derived from this study: PubMed 40854168Chatzikonstantinou T, Vasilopoulou M, Kyrou D, Karakatsoulis G, Argyropaidas P, Besikli-Dimou S, Bonotis P, Chatzimina M, Didi J, Dimosthenous C, Garani-Papadatos T, Hoffman S, Kakalou C, Kazantzaki E, Kiefer S, Koumakis L, Ling J, Maramis C, Meyerheim M, Payne C, Papangelou C, Payne S, Pontikoglou C, Reston R, Ryblom H, Sander A, Schera F, Smedby KE, Zacharioudakis G, Chatzidimitriou A, Doubek M, Stavroyianni N, Ghia P, Papadaki HA, Rosenquist R, Graf N, Natsiavas P, Stamatopoulos K, Karamanidou C, Scarfo L. Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. JCO Oncol Pract. 2026 Jul;22(7):1227-1237. doi: 10.1200/OP-25-00087. Epub 2025 Aug 25.
- Derived from this study: PubMed 40278640Bonotis P, Angelidis P, Natsiavas P. Usability and User Experience Testing of a Co-Designed Electronic Patient-Reported Outcomes App ("MyPal for Adults") for Palliative Cancer Care: Mixed Methods Study. JMIR Hum Factors. 2025 Apr 24;12:e57342. doi: 10.2196/57342.
- Derived from this study: PubMed 37738323Payne S, Begovic D, Salifu Y, Nelson A, Payne C, Downing J, Natsiavas P, Ling J. Applying Digital Health in Cancer and Palliative Care in Europe: Policy Recommendations from an International Expert Workshop (MyPal Project). J Palliat Med. 2024 Feb;27(2):216-223. doi: 10.1089/jpm.2023.0309. Epub 2023 Sep 22.
- Derived from this study: PubMed 34728446Scarfo L, Karamanidou C, Doubek M, Garani-Papadatos T, Didi J, Pontikoglou C, Ling J, Payne C, Papadaki HAlpha, Rosenquist R, Stavroyianni N, Payne S, Ghia P, Natsiavas P, Maramis C, Stamatopoulos K. MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. BMJ Open. 2021 Nov 2;11(11):e050256. doi: 10.1136/bmjopen-2021-050256.
- Individual participant dataSharing planned: No
Related trials for Chronic Lymphocytic Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paolo Ghia, MD,PhD principal investigator
IRCCS San Raffaele
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Administration of the MyPal ePRO system in people with Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes, run by Centre for Research and Technology Hellas at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Paolo Ghia, Prof. (00390226433919 ext. 3919, ghia.paolo@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire (time frame: through study completion, an average of 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04370457, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2021.